Biomedicine & Pharmacotherapy

Cancer therapy shows promise against tuberculosis

Retrieved on: 
Thursday, November 16, 2023
Texas Biomedical Research Institute, Apoptosis, Granuloma, Research, SAN, Immune system, Miliary tuberculosis, Protein, Macrophage, Mouse, Patient, Multimedia, Biomedicine & Pharmacotherapy, FDA, Death, Vaccine, Immunotherapy, Infection, Neoplasm, Drug resistance, Bacteria, Cancer, Human, Doctor of Philosophy, Growth, Volunteering, Cell, Tuberculosis, TB, Pharmaceutical industry, MD

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points: 
  • SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
  • - Larry Schlesinger, MD
    Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
  • The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
  • That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Retrieved on: 
Wednesday, June 8, 2022
Conditional sentence, BD2, Apabetalone, Chromatin, Company, Research, Cell, US Foods, Cell death, Food, Legislation, BRD4, Nature, News, Beti, Disease, Inflammation, Senior, End organ damage, Breakthrough therapy, Fabry disease, BET, Cardiovascular disease, FDA, GLOBE, Patient, TAD, Biomedicine & Pharmacotherapy, COVID-19, Risk, Research and development, TSX, Industry, Virus, Human body, Pharmacology, Intention, Safety, SEDAR, Online gambling, Pharmaceutical industry, Medical device, Fabry

The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.

Key Points: 
  • The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.
  • BD2-selective inhibitors, such as apabetalone, can inhibit the expression of disease-causing genes without disrupting the fundamental functions of cells.
  • The article details the beneficial impacts of apabetalone treatment on inflammatory pathways in immune cells from Fabry disease patients.
  • These findings suggest that apabetalone is a promising therapeutic candidate for the rare disorder.

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

Retrieved on: 
Wednesday, February 16, 2022
CEO, Depression, Company, Holding, OTCQB, United States Patent and Trademark Office, Pain disorder, Biomedicine & Pharmacotherapy, Pain, Mental health, Betaine, Patent, Method, FDA, Suicidal ideation, Ketamine, Post-traumatic stress disorder, Composition, Mouse, CSE, Research, Pharmacotherapy, GLOBE, Substance abuse, Chronic pain, Pharmaceutical industry

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the United States Patent and Trademark Office granted to the Company U.S. Patent No.

Key Points: 
  • TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the United States Patent and Trademark Office granted to the Company U.S. Patent No.
  • 11,213,495, titled "Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine.
  • The patent refers to the combination formulation of FDA-approved ketamine and betaine anhydrous (KETABET), which has been shown in research to enhance the antidepressant effect while potentially reducing the known negative side effects of ketamine significantly.
  • PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of specialty ketamine pharmaceuticals for mental health, neurological, and pain disorders.

PharmaTher Announces Publication of Research Data for KETABET™

Retrieved on: 
Tuesday, January 4, 2022
Twitter, Pharmacotherapy, Post-traumatic stress disorder, Addiction, Anesthesia, Substance abuse, Suicidal ideation, FDA, Amyotrophic lateral sclerosis, GLOBE, OTCQB, Lists of diseases, NMDA, Company, Government budget balance, Betaine, Pain, Holding, USP, Pain disorder, Mental health, Depression, Composition, Patient, Mouse, Chronic pain, Patent, CSE, LTP, LinkedIn, Method, National Health Research Institutes, Biomedicine & Pharmacotherapy, Pharmaceutical industry, Ketamine

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a life sciences company focused on the development and commercialization of specialty ketamine prescription-based products, today announced the publication of a scientific article demonstrating the potential of KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain. The article titled, "Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice", is published in Biomedicine & Pharmacotherapy and can be found here.

Key Points: 
  • Based on the outcome from the ongoing observational studies, the Company will advance the KETABET program with its microneedle patch technology in Phase 2 clinical studies in H2-2022.
  • The present published study aimed to assess whether repeated co-treatment with betaine and ketamine improved behavioral impairments and hippocampal synaptic plasticity.
  • As such, we remain focused on expanding our clinical programs with KETABET for FDA approval.
  • PharmaTher has an exclusive license agreement with the National Health Research Institutes to develop and commercialize of the intellectual portfolio protecting KETABET, the patent titled "Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine".

Emerald Health Pharmaceuticals’ Novel Drug Candidate Demonstrates Significant Anti-inflammatory and Anti-fibrotic Activity in Multi-organ Fibrosis Preclinical Model

Retrieved on: 
Thursday, December 2, 2021
Emerald, Lung, Gastrointestinal tract, Company, EHP, MD, Central nervous system, Doctor of Philosophy, Hope, GLOBE, Biomedicine & Pharmacotherapy, CA, Atherosclerosis, Immune system, Scleroderma, CNS, CB2, Degenerative disease, Heart, CEO, Cardiac fibrosis, MS, Microdeletion syndrome, HIF, Research, Patient, Macrophage, II, Joint, Pulmonary fibrosis, News, Multiple sclerosis, Forward-looking statement, MBA, Human, Orphan, Mouse, Systemic scleroderma, Angiotensin, FDA, Spasms, Serum, Tissue, Skin, Demyelinating disease, Heart failure, Technology, Toxic epidermal necrolysis, Muscle, Hypertension, Autoimmunity, Inflammation, SAN, Hypertrophy, Pain, Stiffness, Fibrosis, Disease, Pharmaceutical industry, Management, Vaccine

SAN DIEGO, CA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has announced the publication of a scientific article in the peer-reviewed journal, Biomedicine & Pharmacotherapy, highlighting a new study providing additional data supporting the potential of EHP’s patented, first-in-class drug candidate, EHP-101, to treat fibrotic diseases, including cardiac fibrosis and systemic sclerosis (SSc). EHP is currently enrolling patients dosed with oral EHP-101 in a Phase IIa clinical trial for SSc (NCT04166552).

Key Points: 
  • The results of this new study indicate that EHP-101 could offer new opportunities in the treatment ofcardiac fibrosis and other fibrotic diseases.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • Its second product candidate, EHP-102, is in preclinical development and is focused on treating Parkinsons disease and Huntingtons disease.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.

New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Oncology, Other Science, Mental health, Research, Managed care, Infectious diseases, General Health, Hospitals, Science, Sarbecovirus, Zoonoses, Health sciences, Animal diseases, Biomedicine & Pharmacotherapy, Coronavirus disease, Pharmacotherapy, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Coronavirus

View the full release here: https://www.businesswire.com/news/home/20210317005066/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210317005066/en/
    The Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology.
  • Moreover, it is possible that vaccines may require continuous development due to the ongoing mutation of coronavirus into different variants .
  • The article is a collaborative effort which covers the results of two separate studies of the impact of oleandrin and PBI-06150 on SARS-CoV-2.
  • Preliminary discussions with the FDA have resulted in the request for additional studies to explore both efficacy and safety.